Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Springer's Drugs in R&D profile "Testosterone Undecanoate — Schering AG" documents Schering AG's discovery and European development of the depot formulation —…
FierceBiotech notes "AVEED was licensed from Bayer Schering Pharma AG, Germany to Indevus Pharmaceuticals, a company Endo acquired earlier this year," framing…
GEN reported Aveed maintained serum testosterone in normal range for up to 10 weeks at steady state and was approved March 6, 2014 with a REMS — "the fourth…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Indevus Pharmaceuticals acquired U.S. rights to NEBIDO/Aveed (testosterone undecanoate), a long-acting injectable testosterone, from Schering AG (Germany) in July 2005. Terms: up to $30M in upfront and milestone payments ($7.5M upfront, $5M on FDA approval, plus regulatory/commercialization milestones) and 25% of net sales to Schering. Endo Pharmaceuticals later inherited the U.S. rights through its 2009 acquisition of Indevus; Aveed was approved by the FDA in March 2014 with a REMS.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Indevus Pharmaceuticals, Inc. / Schering AG (this deal) | 2005 | $30M | — |
| AstraZeneca plc / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical Co. / Fujisawa Pharmaceutical Co. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon, Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
← Browse all deals · How we score deals
More: 2005 deals